Synlogic Reports Positive Data From Phase 2 Trial Evaluating SYNB1618 - Quick Facts

Synlogic, Inc. (SYBX) reported positive data from clinical studies evaluating both SYNB1618 and SYNB1934 in the treatment of phenylketonuria. The company said SYNB1618 showed clinically meaningful reductions of phenylalanine at several dose levels, across multiple time points, in an interim analysis of the phase 2 SynPheny-1 study. Also, SYNB1934, an optimized strain evolved from SYNB1618, showed two-fold higher activity than SYNB1618 in a head-to-head phase 1 study in healthy volunteers.

Synlogic expects final SynPheny-1 results in the first half of 2022. Based on the favorable clinical data from the SYNB1618 and SYNB1934 programs available to date, the company plans to begin planning for a pivotal phase 3 study for the most promising strain.

Shares of Synlogic were up 17% in pre-market trade on Monday.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT